India, Sept. 3 -- Ultragenyx Pharmaceutical Inc. (RARE) shares are plunging 45% after the company announced that its Phase 3 Aspire study of apazunersen in Angelman syndrome failed to achieve both the primary and key secondary efficacy endpoints.
The stock is currently trading at $14.57, down $11.96 or 45.06%, on the Nasdaq. It opened at $13.99 after closing the previous session at $26.53. The stock has traded between $13.81 and $39.89 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....